Brumme Zabrina, Wang Bingxia, Nair Kriebashne, Brumme Chanson, de Pierres Chantal, Reddy Shabashini, Julg Boris, Moodley Eshia, Thobakgale Christina, Lu Zhigang, van der Stok Mary, Bishop Karen, Mncube Zenele, Chonco Fundisiwe, Yuki Yuko, Frahm Nicole, Brander Christian, Carrington Mary, Freedberg Kenneth, Kiepiela Photini, Goulder Philip, Walker Bruce, Ndung'u Thumbi, Losina Elena
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, USA.
Clin Infect Dis. 2009 Sep 15;49(6):956-64. doi: 10.1086/605503.
The extent to which immunologic and clinical biomarkers influence human immunodeficiency virus type 1 (HIV-1) infection outcomes remains incompletely characterized, particularly for non-B subtypes. On the basis of data supporting in vitro HIV-1 protein-specific CD8 T lymphocyte responses as correlates of immune control in cross-sectional studies, we assessed the relationship of these responses, along with established HIV-1 biomarkers, with rates of CD4 cell count decrease in individuals infected with HIV-1 subtype C.
Bivariate and multivariate mixed-effects models were used to assess the relationship of baseline CD4 cell count, plasma viral load, human leukocyte antigen (HLA) class I alleles, and HIV-1 protein-specific CD8 T cell responses with the rate of CD4 cell count decrease in a longitudinal population-based cohort of 300 therapy-naive, chronically infected adults with baseline CD4 cell counts >200 cells/mm(3) and plasma viral loads >500 copies/mL over a median of 25 months of follow-up.
In bivariate analyses, baseline CD4 cell count, plasma viral load, and possession of a protective HLA allele correlated significantly with the rate of CD4 cell count decrease. No relationship was observed between HIV-1 protein-specific CD8 T cell responses and CD4 cell count decrease. Results from multivariate models incorporating baseline CD4 cell counts (201-350 vs >350 cells/mm(3)), plasma viral load (< or =100,000 vs >100,000 copies/mL), and HLA (protective vs not protective) yielded the ability to discriminate CD4 cell count decreases over a 10-fold range. The fastest decrease was observed among individuals with CD4 cell counts >350 cells/mm(3) and plasma viral loads >100,000 copies/mL with no protective HLA alleles (-59 cells/mm(3) per year), whereas the slowest decrease was observed among individuals with CD4 cell counts 201-350 cells/mm(3), plasma viral loads < or =100,000 copies/mL, and a protective HLA allele (-6 cells/mm(3) per year).
The combination of plasma viral load and HLA class I type, but not in vitro HIV-1 protein-specific CD8 T cell responses, differentiates rates of CD4 cell count decrease in patients with chronic subtype-C infection better than either marker alone.
免疫和临床生物标志物对1型人类免疫缺陷病毒(HIV-1)感染结局的影响程度尚未完全明确,尤其是对于非B亚型。基于横断面研究中支持体外HIV-1蛋白特异性CD8 T淋巴细胞反应作为免疫控制相关因素的数据,我们评估了这些反应以及已确立的HIV-1生物标志物与C亚型HIV-1感染者CD4细胞计数下降率之间的关系。
采用双变量和多变量混合效应模型,在一个基于人群的纵向队列中,评估300名未接受过治疗、慢性感染的成年人的基线CD4细胞计数、血浆病毒载量、人类白细胞抗原(HLA)I类等位基因以及HIV-1蛋白特异性CD8 T细胞反应与CD4细胞计数下降率之间的关系。这些成年人基线CD4细胞计数>200个细胞/mm³,血浆病毒载量>500拷贝/mL,随访时间中位数为25个月。
在双变量分析中,基线CD4细胞计数、血浆病毒载量以及拥有保护性HLA等位基因与CD4细胞计数下降率显著相关。未观察到HIV-1蛋白特异性CD8 T细胞反应与CD4细胞计数下降之间的关系。纳入基线CD4细胞计数(201 - 350 vs>350个细胞/mm³)、血浆病毒载量(≤100,000 vs>100,000拷贝/mL)和HLA(保护性 vs 非保护性)的多变量模型结果显示,能够在10倍范围内区分CD4细胞计数下降情况。CD4细胞计数>350个细胞/mm³且血浆病毒载量>100,000拷贝/mL且无保护性HLA等位基因的个体中,CD4细胞计数下降最快(每年-59个细胞/mm³),而CD4细胞计数201 - 350个细胞/mm³、血浆病毒载量≤100,000拷贝/mL且有保护性HLA等位基因的个体中,CD4细胞计数下降最慢(每年-6个细胞/mm³)。
血浆病毒载量和HLA I类类型的组合,而非体外HIV-1蛋白特异性CD8 T细胞反应,比单独任何一个标志物都能更好地区分慢性C亚型感染患者的CD4细胞计数下降率。